Base de dados : MEDLINE
Pesquisa : D02.886.778.580 [Categoria DeCS]
Referências encontradas : 248 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 25 ir para página                         

  1 / 248 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26196273
[Au] Autor:Serna-Jiménez CE; del Rio-Sancho S; Calatayud-Pascual MA; Balaguer-Fernández C; Femenía-Font A; López-Castellano A; Merino V
[Ad] Endereço:Instituto de Ciencias Biomédicas, Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, 46113 Moncada, Spain. Electronic address: cesar.serna@hotmail.es.
[Ti] Título:Development of antimigraine transdermal delivery systems of pizotifen malate.
[So] Source:Int J Pharm;492(1-2):223-32, 2015 Aug 15.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to develop and evaluate a transdermal delivery system of pizotifen malate. Pizotifen is frequently used in the preventive treatment of migraine, but is also indicated in eating disorders. In the course of the project, the effects of chemical enhancers such as ethanol, 1,8-cineole, limonene, azone and different fatty acids (decanoic, decenoic, dodecanoic, linoleic and oleic acids) were determined, first using a pizotifen solution. Steady state flux, diffusion and partition parameters were estimated by fitting the Scheuplein equation to the data obtained. Among the chemical enhancers studied, decenoic acid showed the highest enhancement activity, which seemed to be due to the length of its alkyl chain and unsaturation at the 9th carbon. The influence of iontophoresis and the involvement of electrotransport in said process was determined. The absorption profile obtained with iontophoresis was similar to that obtained with fatty acids and terpenes, though skin deposition of the drug was lower with the former. Transdermal delivery systems (TDS) of pizotifen were manufactured by including chemical enhancers, decenoic acid or oleic acid, and were subsequently characterized. When the results obtained with solutions were compared with those obtained with the TDS, a positive enhancement effect was observed with the latter with respect to the partitioning and diffusion of the drug across the skin. Our findings endorse the suitability of our TDS for delivering therapeutic amounts of pizotifen malate.
[Mh] Termos MeSH primário: Analgésicos não Entorpecentes/administração & dosagem
Sistemas de Liberação de Medicamentos
Pizotilina/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Analgésicos não Entorpecentes/química
Animais
Azepinas/química
Cicloexanóis/química
Cicloexenos/química
Etanol/química
Ácidos Graxos/química
Técnicas In Vitro
Iontoforese
Transtornos de Enxaqueca/tratamento farmacológico
Monoterpenos/química
Pizotilina/química
Absorção Cutânea
Suínos
Terpenos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Azepines); 0 (Cyclohexanols); 0 (Cyclohexenes); 0 (Fatty Acids); 0 (Monoterpenes); 0 (Terpenes); 0BY8440V3N (Pizotyline); 1F3X9DRV9X (laurocapram); 3K9958V90M (Ethanol); 9MC3I34447 (limonene); RV6J6604TK (eucalyptol)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150814
[Lr] Data última revisão:
150814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150722
[St] Status:MEDLINE


  2 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24669817
[Au] Autor:Ramachandran S; Osterhaus SR; Karp PH; Welsh MJ; McCray PB
[Ad] Endereço:1 Department of Pediatrics.
[Ti] Título:A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function.
[So] Source:Am J Respir Cell Mol Biol;51(3):354-62, 2014 Sep.
[Is] ISSN:1535-4989
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The most common cystic fibrosis (CF) mutation, ΔF508, causes protein misfolding, leading to proteosomal degradation. We recently showed that expression of miR-138 enhances CF transmembrane conductance regulator (CFTR) biogenesis and partially rescues ΔF508-CFTR function in CF airway epithelia. We hypothesized that a genomic signature approach can be used to identify new bioactive small molecules affecting ΔF508-CFTR rescue. The Connectivity Map was used to identify 27 small molecules with potential to restore ΔF508-CFTR function in airway epithelia. The molecules were screened in vitro for efficacy in improving ΔF508-CFTR trafficking, maturation, and chloride current. We identified four small molecules that partially restore ΔF508-CFTR function in primary CF airway epithelia. Of these, pyridostigmine showed cooperativity with corrector compound 18 in improving ΔF508-CFTR function. There are few CF therapies based on new molecular insights. Querying the Connectivity Map with relevant genomic signatures offers a method to identify new candidates for rescuing ΔF508-CFTR function.
[Mh] Termos MeSH primário: Regulador de Condutância Transmembrana em Fibrose Cística/genética
Regulador de Condutância Transmembrana em Fibrose Cística/metabolismo
Regulação da Expressão Gênica
Genômica
[Mh] Termos MeSH secundário: Biperideno/química
Brônquios/metabolismo
Cloretos/química
Biologia Computacional
Fibrose Cística/genética
Genoma Humano
Células HeLa
Seres Humanos
Fenótipo
Pizotilina/química
Transporte Proteico
Brometo de Piridostigmina/química
Mucosa Respiratória/metabolismo
Software
Ácido Valproico/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Chlorides); 0 (cystic fibrosis transmembrane conductance regulator delta F508); 0BY8440V3N (Pizotyline); 0FRP6G56LD (Biperiden); 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator); 614OI1Z5WI (Valproic Acid); KVI301NA53 (Pyridostigmine Bromide)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140328
[St] Status:MEDLINE
[do] DOI:10.1165/rcmb.2014-0007OC


  3 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:24532249
[Au] Autor:Huertas-Ceballos AA; Logan S; Bennett C; Macarthur C; Martin AE
[Ad] Endereço:Neonatal Unit, Women's Health, UCLH, Neonatal office 2nd floor North, 250 Euston Road, London, UK, NW1 2PG.
[Ti] Título:WITHDRAWN: Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.
[So] Source:Cochrane Database Syst Rev;(2):CD003017, 2014 Feb 17.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Dor Abdominal/tratamento farmacológico
Analgésicos não Entorpecentes/uso terapêutico
Síndrome do Intestino Irritável/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Famotidina/uso terapêutico
Seres Humanos
Pizotilina/uso terapêutico
Óleos Vegetais/uso terapêutico
Recidiva
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Plant Oils); 0BY8440V3N (Pizotyline); 5QZO15J2Z8 (Famotidine); AV092KU4JH (peppermint oil)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:160602
[Lr] Data última revisão:
160602
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140218
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003017.pub3


  4 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24466319
[Au] Autor:Lin OA; Karim ZA; Vemana HP; Espinosa EV; Khasawneh FT
[Ad] Endereço:Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, United States of America.
[Ti] Título:The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function.
[So] Source:PLoS One;9(1):e87026, 2014.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There is considerable interest in defining new agents or targets for antithrombotic purposes. The 5-HT2A receptor is a G-protein coupled receptor (GPCR) expressed on many cell types, and a known therapeutic target for many disease states. This serotonin receptor is also known to regulate platelet function. Thus, in our FDA-approved drug repurposing efforts, we investigated the antiplatelet activity of cyproheptadine and pizotifen, two antidepressant 5-HT2A Receptor antagonists. Our results revealed that cyproheptadine and pizotifen reversed serotonin-enhanced ADP-induced platelet aggregation in vitro and ex vivo. And the inhibitory effects of these two agents were found to be similar to that of EMD 281014, a 5-HT2A Receptor antagonist under development. In separate experiments, our studies revealed that these 5-HT2A receptor antagonists have the capacity to reduce serotonin-enhanced ADP-induced elevation in intracellular calcium levels and tyrosine phosphorylation. Using flow cytometry, we also observed that cyproheptadine, pizotifen, and EMD 281014 inhibited serotonin-enhanced ADP-induced phosphatidylserine (PS) exposure, P-selectin expression, and glycoprotein IIb-IIIa activation. Furthermore, using a carotid artery thrombosis model, these agents prolonged the time for thrombotic occlusion in mice in vivo. Finally, the tail-bleeding time was investigated to assess the effect of cyproheptadine and pizotifen on hemostasis. Our findings indicated prolonged bleeding time in both cyproheptadine- and pizotifen-treated mice. Notably, the increases in occlusion and bleeding times associated with these two agents were comparable to that of EMD 281014, and to clopidogrel, a commonly used antiplatelet drug, again, in a fashion comparable to clopidogrel and EMD 281014. Collectively, our data indicate that the antidepressant 5-HT2A antagonists, cyproheptadine and pizotifen do exert antiplatelet and thromboprotective effects, but similar to clopidogrel and EMD 281014, their use may interfere with normal hemostasis.
[Mh] Termos MeSH primário: Antidepressivos/farmacologia
Trombose das Artérias Carótidas/tratamento farmacológico
Ciproeptadina/farmacologia
Pizotilina/farmacologia
Inibidores da Agregação de Plaquetas/farmacologia
Agregação Plaquetária/fisiologia
Serotonina/farmacologia
[Mh] Termos MeSH secundário: Difosfato de Adenosina/farmacologia
Animais
Western Blotting
Cálcio/metabolismo
Trombose das Artérias Carótidas/metabolismo
Trombose das Artérias Carótidas/patologia
Citometria de Fluxo
Hemorragia/tratamento farmacológico
Hemorragia/metabolismo
Hemorragia/patologia
Seres Humanos
Imunoprecipitação
Indóis/farmacologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Piperazinas/farmacologia
Ativação Plaquetária/efeitos dos fármacos
Agregação Plaquetária/efeitos dos fármacos
Testes de Função Plaquetária
Receptor 5-HT2A de Serotonina/química
Antagonistas da Serotonina/farmacologia
Agonistas de Receptores de Serotonina/farmacologia
Ticlopidina/análogos & derivados
Ticlopidina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (EMD 281014); 0 (Indoles); 0 (Piperazines); 0 (Platelet Aggregation Inhibitors); 0 (Receptor, Serotonin, 5-HT2A); 0 (Serotonin Antagonists); 0 (Serotonin Receptor Agonists); 0BY8440V3N (Pizotyline); 2YHB6175DO (Cyproheptadine); 333DO1RDJY (Serotonin); 61D2G4IYVH (Adenosine Diphosphate); A74586SNO7 (clopidogrel); OM90ZUW7M1 (Ticlopidine); SY7Q814VUP (Calcium)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140128
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0087026


  5 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23416816
[Au] Autor:Israil A; Ahmed S; Rahman KM; Uddin MJ; Dey SK; Battacharjee M; Mondal G; Ali MA; Alam MN; Miah AH; Uddin MS
[Ad] Endereço:Department of Neurology, National Institute of Neuroscience, Sher-e-Bangla Nagar, Dhaka, Bangladesh.
[Ti] Título:Efficacy of amitriptyline, pizotifen and propranolol in the prevention of migraine.
[So] Source:Mymensingh Med J;22(1):93-100, 2013 Jan.
[Is] ISSN:1022-4742
[Cp] País de publicação:Bangladesh
[La] Idioma:eng
[Ab] Resumo:This intervention study conducted in the Neurology outpatient Department of Mymensingh Medical College Hospital (MMCH) from January 2006 to December 2007 to compare efficacy of amitriptyline, pizotifen and propranolol in the prophylaxis of migraine. Ninety cases were selected following certain inclusion and exclusion criteria. Result showed that the differences in duration, frequency and severity of attack were reduced in all groups but the differences among the groups were not significant (p>0.05). However, compared with amitriptyline and pizotifen, the propranolol group needed tablet paracetamol as abortive therapy less frequently which was statistically significant (p<0.05). All the drugs were well tolerated with minimum adverse effects.
[Mh] Termos MeSH primário: Amitriptilina/uso terapêutico
Analgésicos não Entorpecentes/uso terapêutico
Transtornos de Enxaqueca/prevenção & controle
Pizotilina/uso terapêutico
Propranolol/uso terapêutico
Vasodilatadores/uso terapêutico
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Adolescente
Adulto
Antieméticos/uso terapêutico
Criança
Domperidona/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Antiemetics); 0 (Vasodilator Agents); 0BY8440V3N (Pizotyline); 1806D8D52K (Amitriptyline); 362O9ITL9D (Acetaminophen); 5587267Z69 (Domperidone); 9Y8NXQ24VQ (Propranolol)
[Em] Mês de entrada:1306
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130219
[St] Status:MEDLINE


  6 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23336713
[Au] Autor:Santos CM; Francischi JN; Lima-Paiva P; Sluka KA; Resende MA
[Ad] Endereço:Post Graduate Program in Sciences of Rehabilitation, Department of Physical Therapy, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
[Ti] Título:Effect of transcutaneous electrical stimulation on nociception and edema induced by peripheral serotonin.
[So] Source:Int J Neurosci;123(7):507-15, 2013 Jul.
[Is] ISSN:1563-5279
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Transcutaneous electrical nerve stimulation (TENS) is defined as the application of an electrical current to the skin through surface electrodes for pain relief. Various theories have been proposed in order to explain the analgesic mechanism of TENS. Recent studies have demonstrated that part of this analgesia is mediated through neurotransmitters acting at peripheral sites. The aim of this study was to investigate the effects of low frequency (LF: 10 HZ) TENS and high frequency (HF: 130 HZ) TENS on hyperalgesia and edema when applied before the serotonin (5-HT) administered into the rat paw. LF and HF TENS were applied to the right paw for 20 min, and 5-HT was administered immediately after TENS. The Hargreaves method was used to measure nociception, while the hydroplethysmometer (Ugo Basile®) was used to measure edema. Neither HF nor LF TENS inhibited 5-HT-induced edema. However, LF TENS, but not HF TENS, completely reduced 5-HT-induced hyperalgesia. Pre-treatment of the paw with naltrexone, prior to application of TENS, (Nx: 50 µg; I.pl.) showed a complete blockade of the analgesic effect induced by low frequency TENS. Thus, our results confirmed the lack of an anti-inflammatory effect through the use of TENS as well as the participation of peripheral endogenous opioid receptors in LF TENS analgesia in addition to its central action.
[Mh] Termos MeSH primário: Edema/induzido quimicamente
Edema/prevenção & controle
Hiperalgesia/prevenção & controle
Nociceptividade/fisiologia
Serotonina/efeitos adversos
Estimulação Elétrica Nervosa Transcutânea
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Metisergida/farmacologia
Naltrexona/farmacologia
Antagonistas de Entorpecentes/farmacologia
Pizotilina/farmacologia
Ratos
Antagonistas da Serotonina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Narcotic Antagonists); 0 (Serotonin Antagonists); 0BY8440V3N (Pizotyline); 333DO1RDJY (Serotonin); 5S6W795CQM (Naltrexone); XZA9HY6Z98 (Methysergide)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:130614
[Lr] Data última revisão:
130614
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130123
[St] Status:MEDLINE
[do] DOI:10.3109/00207454.2013.768244


  7 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:23393546
[Au] Autor:Sarantos MR; Papanikolaou T; Ellerby LM; Hughes RE
[Ad] Endereço:The Buck Institute for Research on Aging, Novato, CA 94945, USA.
[Ti] Título:Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.
[So] Source:J Huntingtons Dis;1(2):195-210, 2012.
[Is] ISSN:1879-6400
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Huntington's disease (HD) is a dominantly inherited neurodegenerative condition characterized by dysfunction in striatal and cortical neurons. There are currently no approved drugs known to slow the progression of HD. OBJECTIVE: To facilitate the development of therapies for HD, we identified approved drugs that can ameliorate mutant huntingtin-induced toxicity in experimental models of HD. METHODS: A chemical screen was performed in a mouse Hdh(Q111/Q111) striatal cell model of HD. This screen identified a set of structurally related approved drugs (pizotifen, cyproheptadine, and loxapine) that rescued cell death in this model. Pizotifen was subsequently evaluated in the R6/2 HD mouse model. RESULTS: We found that in striatal Hdh(Q111/Q111) cells, pizotifen treatment caused transient ERK activation and inhibition of ERK activation prevented rescue of cell death in this model. In the R6/2 HD mouse model, treatment with pizotifen activated ERK in the striatum, reduced neurodegeneration and significantly enhanced motor performance. CONCLUSIONS: These results suggest that pizotifen and related approved drugs may provide a basis for developing disease modifying therapeutic interventions for HD.
[Mh] Termos MeSH primário: Corpo Estriado/metabolismo
Doença de Huntington/tratamento farmacológico
Doença de Huntington/prevenção & controle
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Neurônios/metabolismo
Pizotilina/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Células Cultivadas
Corpo Estriado/efeitos dos fármacos
Relação Dose-Resposta a Droga
Doença de Huntington/diagnóstico
Camundongos
Camundongos Transgênicos
Neurônios/efeitos dos fármacos
Neurônios/patologia
Fármacos Neuroprotetores/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Neuroprotective Agents); 0BY8440V3N (Pizotyline)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130209
[St] Status:MEDLINE
[do] DOI:10.3233/JHD-120033


  8 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22002332
[Au] Autor:Serna-Jiménez CE; del Rio Sancho S; Calatayud-Pascual MA; Balaguer-Fernández C; Femenía-Font A; López-Castellano A; Merino V
[Ad] Endereço:Departamento de Fisiología, Farmacología y Toxicología, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Ed. Seminario s/n, 46113, Moncada, Valencia, Spain. cesar.serna@uch.ceu.es
[Ti] Título:HPLC-UV analytical method for determination of pizotifen after in vitro transdermal diffusion studies.
[So] Source:Biomed Chromatogr;26(6):769-74, 2012 Jun.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Pizotifen malate is an antihistamine and serotonin inhibitor used in the preventive treatment of migraine and eating disorders. A simple, rapid, accurate and precise high-performance liquid chromatography (HPLC) method involving ultraviolet detection was validated for the quantitative analysis of pizotifen malate in samples from in vitro transdermal diffusion studies. The method was validated for specificity, linearity, accuracy, precision, limit of detection, limit of quantification and robustness. Drug stability in the solution was also determined under different conditions. Separation was carried out using a 250 × 4.0 mm Kromasil(®) C(18) column at room temperature. The detector response, fitted at 254 nm, was found to be linear in a concentration range between 0.24 and 24.0 µg/mL. The limit of detection was 0.02 µg/mL and the limit of quantification was 0.07 µg/mL. Finally, in vitro transdermal diffusion of pizotifen malate was characterized using the validated HPLC method.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Pizotilina/análise
Pele/metabolismo
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Difusão
Cultura em Câmaras de Difusão
Estabilidade de Medicamentos
Limite de Detecção
Modelos Lineares
Pizotilina/administração & dosagem
Pizotilina/química
Reprodutibilidade dos Testes
Absorção Cutânea
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0BY8440V3N (Pizotyline)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111018
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.1727


  9 / 248 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:20884459
[Au] Autor:Rahman SM; Lutfulkabir A; Jahan MD; Momen AZ; Rouf AS
[Ad] Endereço:Department of Pharmaceutical Technology, University of Dhaka, Dhaka-1000, Bangladesh.
[Ti] Título:Validation and application of reversed phase high-performance liquid chromatographic method for quantification of pizotifen malate in pharmaceutical solid dosage formulations.
[So] Source:Pak J Pharm Sci;23(4):435-41, 2010 Oct.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to develop and validate an isocratic reversed phase high-performance liquid chromatographic method for quantification of pizotifen malate in pharmaceutical solid dosage formulations. Good chromatographic separation of pizotifen malate was achieved by using an analytical column, C(18) ODS column. The system was operated at 40°C oven temperature using a mobile phase consisting of acetonitrile and acetate buffer pH 7.0 (60:40) at a flow rate of 2 ml/min. The method showed high sensitivity with good linearity (r(2)= 0.99997) over the tested concentration range of 0.0020-0.0300 mg/ml for pizotifen malate. Detection was carried out at 231 nm and retention time was 2.838 min. Placebo and blank studies were performed and no peak was observed at the retention time of pizotifen malate. The intermediate precision and accuracy results (mean ± RSD, n=3) were (99.11±0.21) % and (99.19±0.55) % respectively with tailing factor (1.26±0.19). The proposed method was validated in terms of selectivity, linearity, accuracy, precision, range, detection and quantitation limit, system suitability and solution stability.This method can be successfully employed for simultaneous quantitative analysis of pizotifen malate in pharmaceutical solid dosage formulations.
[Mh] Termos MeSH primário: Pizotilina/análise
Antagonistas da Serotonina/análise
[Mh] Termos MeSH secundário: Química Farmacêutica
Cromatografia Líquida de Alta Pressão
Formas de Dosagem
Indicadores e Reagentes
Análise de Regressão
Reprodutibilidade dos Testes
Soluções
Espectrofotometria Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dosage Forms); 0 (Indicators and Reagents); 0 (Serotonin Antagonists); 0 (Solutions); 0BY8440V3N (Pizotyline)
[Em] Mês de entrada:1101
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101002
[St] Status:MEDLINE


  10 / 248 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20571104
[Au] Autor:Elouni B; Ben Salem C; Zamy M; Poupon R; Bouraoui K; Biour M
[Ti] Título:Fulminant hepatitis possibly related to pizotifen therapy.
[So] Source:Ann Pharmacother;44(7-8):1348-9, 2010 Jul-Aug.
[Is] ISSN:1542-6270
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Falência Hepática Aguda/induzido quimicamente
Pizotilina/efeitos adversos
Antagonistas da Serotonina/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Falência Hepática Aguda/cirurgia
Transplante de Fígado
Masculino
Transtornos de Enxaqueca/tratamento farmacológico
Pizotilina/uso terapêutico
Antagonistas da Serotonina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Serotonin Antagonists); 0BY8440V3N (Pizotyline)
[Em] Mês de entrada:1010
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100624
[St] Status:MEDLINE
[do] DOI:10.1345/aph.1P186



página 1 de 25 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde